Gilead Stock SURGES! $800 Million HIV Drug SHOCKS Wall Street (But There’s a Catch!)
Could a single HIV prevention drug truly generate nearly a billion dollars in sales this year? Gilead stock just experienced a significant rebound, soaring higher after remarkably beating Wall Street's fourth-quarter expectations. The excitement stems from strong guidance for its twice-yearly HIV prevention shot, Yeztugo, which is projected to bring in $800 million in sales this year. However, this impressive outlook still falls short of some buy-side estimates of one billion dollars, creating an interesting divergence in market sentiment. Stay tuned as we track this pharmaceutical giant's journey; make sure to subscribe to our channel for the latest updates.
Tags/Hashtags: #gilead #gild #yeztugo #stock #investing #sales #analyst #gild #yeztugo
Leave a Reply